Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy

Prakash Ambady, Matthias Holdhoff, David Bonekamp, Fay Wong, Stuart A. Grossman

Research output: Contribution to journalArticle

Abstract

Treatment of patients with newly diagnosed primary CNS lymphomas using high dose methotrexate regimens is reported to yield about 30% long term survivors with minimal neurotoxicity. As in other systemic large cell lymphomas, it is generally assumed that most relapses occur within 5 years of diagnosis. A retrospective review of the Johns Hopkins experience in 52 patients treated between 1995 and 2008 yielded 19 patients (37%) who achieved a complete response and were followed for over 5 years. Four of these patients remained progression-free for over 10 years. However, two of these long-term survivors have now relapsed over 10 years after their initial diagnosis. An analysis of progression and overall survival does not reveal a plateau suggesting that even patients who have not recurred for over 10 years remain at high risk for relapse after treatment with single agent high dose methotrexate.

Original languageEnglish (US)
Pages (from-to)393-398
Number of pages6
JournalCNS oncology
Volume4
Issue number6
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Methotrexate
Lymphoma
Recurrence
Survivors
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. / Ambady, Prakash; Holdhoff, Matthias; Bonekamp, David; Wong, Fay; Grossman, Stuart A.

In: CNS oncology, Vol. 4, No. 6, 2015, p. 393-398.

Research output: Contribution to journalArticle

Ambady, Prakash ; Holdhoff, Matthias ; Bonekamp, David ; Wong, Fay ; Grossman, Stuart A. / Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. In: CNS oncology. 2015 ; Vol. 4, No. 6. pp. 393-398.
@article{8c562c30036142fcb8e41f33fcb01787,
title = "Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy",
abstract = "Treatment of patients with newly diagnosed primary CNS lymphomas using high dose methotrexate regimens is reported to yield about 30{\%} long term survivors with minimal neurotoxicity. As in other systemic large cell lymphomas, it is generally assumed that most relapses occur within 5 years of diagnosis. A retrospective review of the Johns Hopkins experience in 52 patients treated between 1995 and 2008 yielded 19 patients (37{\%}) who achieved a complete response and were followed for over 5 years. Four of these patients remained progression-free for over 10 years. However, two of these long-term survivors have now relapsed over 10 years after their initial diagnosis. An analysis of progression and overall survival does not reveal a plateau suggesting that even patients who have not recurred for over 10 years remain at high risk for relapse after treatment with single agent high dose methotrexate.",
author = "Prakash Ambady and Matthias Holdhoff and David Bonekamp and Fay Wong and Grossman, {Stuart A.}",
year = "2015",
doi = "10.2217/cns.15.34",
language = "English (US)",
volume = "4",
pages = "393--398",
journal = "CNS oncology",
issn = "2045-0915",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy

AU - Ambady, Prakash

AU - Holdhoff, Matthias

AU - Bonekamp, David

AU - Wong, Fay

AU - Grossman, Stuart A.

PY - 2015

Y1 - 2015

N2 - Treatment of patients with newly diagnosed primary CNS lymphomas using high dose methotrexate regimens is reported to yield about 30% long term survivors with minimal neurotoxicity. As in other systemic large cell lymphomas, it is generally assumed that most relapses occur within 5 years of diagnosis. A retrospective review of the Johns Hopkins experience in 52 patients treated between 1995 and 2008 yielded 19 patients (37%) who achieved a complete response and were followed for over 5 years. Four of these patients remained progression-free for over 10 years. However, two of these long-term survivors have now relapsed over 10 years after their initial diagnosis. An analysis of progression and overall survival does not reveal a plateau suggesting that even patients who have not recurred for over 10 years remain at high risk for relapse after treatment with single agent high dose methotrexate.

AB - Treatment of patients with newly diagnosed primary CNS lymphomas using high dose methotrexate regimens is reported to yield about 30% long term survivors with minimal neurotoxicity. As in other systemic large cell lymphomas, it is generally assumed that most relapses occur within 5 years of diagnosis. A retrospective review of the Johns Hopkins experience in 52 patients treated between 1995 and 2008 yielded 19 patients (37%) who achieved a complete response and were followed for over 5 years. Four of these patients remained progression-free for over 10 years. However, two of these long-term survivors have now relapsed over 10 years after their initial diagnosis. An analysis of progression and overall survival does not reveal a plateau suggesting that even patients who have not recurred for over 10 years remain at high risk for relapse after treatment with single agent high dose methotrexate.

UR - http://www.scopus.com/inward/record.url?scp=85013697434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013697434&partnerID=8YFLogxK

U2 - 10.2217/cns.15.34

DO - 10.2217/cns.15.34

M3 - Article

VL - 4

SP - 393

EP - 398

JO - CNS oncology

JF - CNS oncology

SN - 2045-0915

IS - 6

ER -